The effective combination therapies with irinotecan for colorectal cancer
Frontiers in Pharmacology · 05.02.2024 · 15
DOI: 10.3389/fphar.2024.1356708 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.02.2024. Verfasst von Yun Chai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundam…. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Colorectal cancer is the third most common type of cancer worldwide and has become one of the major human disease burdens. In clinical practice, the treatment of colorectal cancer has been closely related to the use of irinotecan. Irinotecan combines with many other anticancer drugs and has a broader range of drug combinations. Combination therapy is one of the most important means of improving anti-tumor efficacy and overcoming drug resistance. Reasonable combination therapy can lead to better patient treatment options, and inappropriate combination therapy will increase patient risk. For the colorectal therapeutic field, the significance of combination therapy is to improve the efficacy, reduce the adverse effects, and improve the ease of treatment. Therefore, we explored the clinical advantages of its combination therapy based on mechanism or metabolism and reviewed the rationale basis and its limitations in conducting exploratory clinical trials on irinotecan combination therapy, including the results of clinical trials on the combination potentiation of cytotoxic drugs, targeted agents, and herbal medicine. We hope that these can evoke more efforts to conduct irinotecan in the laboratory for further studies and evaluations, as well as the possibility of more in-depth development in future clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine,…
- State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao SAR, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chai, Y., Liu, J. L., Zhang, S., Li, N., Xu, D. Q., Liu, W. J., Fu, R. J., & Tang, Y. P. (2024). The effective combination therapies with irinotecan for colorectal cancer. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1356708
Vancouver
Chai Y, Liu JL, Zhang S, Li N, Xu DQ, Liu WJ, et al. The effective combination therapies with irinotecan for colorectal cancer. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1356708
BibTeX
@article{Chai2024,
author = {Chai, Yun and Liu, Jing-Li and Zhang, Shuo and Li, Na and Xu, Ding-Qiao and Liu, Wen-Juan and Fu, Rui-Jia and Tang, Yu-Ping},
title = {The effective combination therapies with irinotecan for colorectal cancer},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1356708}
}
EUVIMED